• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Central, Searchable Repository for all COVID-19 Clinical Trials Launches

by Fred Pennic 04/14/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Central, Searchable Repository for all COVID-19 Clinical Trials Launches

What You Need to Know:

– Inato unveils central, searchable repository for all COVID-19 clinical trials designed to support clinical researchers, physicians, and biopharma organizations.

– By centralizing all clinical studies being conducted worldwide and updating trial trends with new information from public registries and aggregators daily, Inato seeks to optimize COVID-19 clinical trial resource allocation and help address any unmet needs as quickly as possible. 


Paris-based (and Obvious Ventures-backed) Inato unveiled its anti-covid platform today, a comprehensive, easily searchable, central repository for all existing clinical trials for SARS-CoV2 (the virus responsible for COVID-19). The anticovid platform is public, free to access and offers extensive search and filtering capabilities — a unique and critical feature given the unprecedented pace at which COVID-19 clinical trial research is evolving.

anticovid Platform Background/Methodology

Trials listed in Anticovid mainly come from public registries or aggregators, including WHO clinical trials registry platform, clinicaltrials.gov, chictr.org.cn, and clinicaltrialsregister.eu. However, there was to our knowledge no unique and centralized repository where all clinical studies conducted worldwide on COVID-19 could be found.

The purpose of Inato’s anticovid platform is to provide the global healthcare community with easy and efficient access to any available COVID-19 trial information and research trends. By centralizing all clinical studies being conducted worldwide and updating trial trends with new information from public registries and aggregators daily, Inato seeks to optimize COVID-19 clinical trial resource allocation and help address any unmet needs as quickly as possible.

Clinical Research for Covid-19

In addition to its detailed search and filtering capabilities, the anticovid platform analyzes the latest COVID-19 clinical trial information, providing platform subscribers new analysis twice per week. Most recently, the platform deduced that:

– Nearly 1,000 COVID-19 trials were launched or anticipated in the past 4 months. This equates to an average of 210 trials per month, compared to just 40 breast cancer trials per month and 1 malaria trial per month.

– While China remains responsible for the most trials, other highly affected, developed countries are quickly gaining speed. For example, Italy, France and the U.S. have significantly grown their contributions in recent weeks.

– Early signals suggest some antiviral agents could be ineffective for treating COVID-19 (at least in seriously ill patients), however a significant focus of trials remains on those drugs.

– Chloroquine/hydroxychloroquine is also a focus, with more than 50,000 participants currently participating in this therapeutic class of trials in the U.S.

– The most frequently tested therapeutic classes are antiviral agents, Chloroquine/Hydroxychloroquine and traditional/Chinese medicine

“We’ve been tracking COVID-19 clinical trials since January and noticed how difficult it was to consolidate, compare and take action on the hundreds upon hundreds of trials being developed,” said Inato Co-Founder and CEO Kourosh Davarpanah. “Our company’s objective is to bring new doctors and their patients into the clinical research ecosystem to unlock the potential of unengaged research sites so biopharma can bring innovative therapies to market faster. With our anticovid platform, we’re taking things one step further by centralizing all COVID-19 clinical trial information and making it easy to navigate so that clinical researchers, physicians and biopharma companies can more efficiently participate in the fight for a cure.”

Availability

To access Inato’s anticovid platform, visit https://covid.inato.com/analysis.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Clinical Trials, Coronavirus (COVID-19)

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |